Résumé
OBJECTIVES@#To investigate the effectiveness and safety of Xingnaojing Injection (XNJ, ) compared with naloxone for the treatment of acute alcohol intoxication (AAI), and provide the latest evidence through evidence-based approach.@*METHODS@#Seven electro-databases including PubMed, EMBASE, Cochrane Central Register of Controlled Trials, Chinese National Knowledge Infrastructure Databases, Chinese Biomedical Literature Database, Chinese Science and Technology Periodical Database (VIP) and Wanfang Database were searched from the inception to January 2018. Randomized controlled trials (RCTs) comparing XNJ with naloxone for patients with AAI and reporting at least one of the below outcomes were included: patients' conscious recovery time, stay length in emergency department, disappearance time of the ataxia symptom, the severity of the symptoms, the blood alcohol content as well as the adverse events. Methodological quality of included trials was assessed using the risk of bias tool which recommended by the Cochrane Collaboration. Meta-analysis was conducted by Review Manager 5.3 software.@*RESULTS@#Totally 141 trials with 13,901 patients were included in this review, all of them were assessed as unclear or high risk of bias. Results showed that on the basis of routine therapy, standard dose XNJ (10-20 mL) may have similar results with naloxone on the recovery time of consciousness (MD 12 min, 95% CI 7.2-17.4 min) and disappearance time of symptoms (MD 6 min, 95% CI-13.8-25.8 min) for patients with AAI. Larger dose of XNJ Injection (21-40 mL) may speed up the time (almost 1 h earlier). Combination of XNJ and naloxone seemed superior to the naloxone alone for all the relevant outcomes. The average difference of time in consciousness recovery was 2 h and the number of AAI patients whose consciousness recovery within 1 h was above 50% the combination group than in the control group (RR 1.42, 95% CI 1.29 to 1.56). No severe adverse events or adverse reactions of XNJ were reported in the included trials.@*CONCLUSIONS@#Low quality of evidence showed XNJ may have equal effect as naloxone and may achieve better effect as add-on intervention with naloxone for patients with AAI. We failed to evaluate the safety of XNJ Injection due to the insufficient evidence in this review. Registration number. in PROSPERO (No. CRD42018087804).
Résumé
RESUMO JUSTIFICATIVA E OBJETIVOS: A neurólise do plexo celíaco é uma opção de tratamento da dor para pacientes com câncer abdominal refratário a outras abordagens. É acompanhada de reações adversas que são diagnosticadas e tratadas desde que o paciente receba monitorização e acompanhamento imediato após o procedimento. O objetivo deste estudo foi relatar o caso de uma paciente submetida a neurólise de plexo celíaco, evoluindo com sintomas de intoxicação alcoólica aguda diagnosticada na sala de recuperação pós-anestésica. RELATO DO CASO: Paciente do gênero feminino, 43 anos, com neoplasia de cabeça de pâncreas submetida a neurólise de plexo celíaco intraoperatório com 40mL de álcool a 98%, evolui na sala de recuperação pós-anestésica com hipotensão, hipoxemia e confusão mental, sintomas esses revertidos com hidratação por via venosa e elevação de membros inferiores. CONCLUSÃO: A alcoolização do plexo celíaco bloqueia definitivamente a dor visceral de pacientes com neoplasia de pâncreas, porém não está isenta de reações adversas, as quais podem evoluir para complicações graves caso não sejam prontamente diagnosticadas, tornando-se imprescindível o acompanhamento do paciente na sala de recuperação pós-anestésica.
ABSTRACT BACKGROUND AND OBJECTIVES: Celiac plexus neurolysis is a pain management option for patients with abdominal cancer refractory to other approaches. It is followed by adverse reactions which may be diagnosed and treated, provided patients are monitored and followed up immediately after the procedure. This study aimed at reporting the case of a patient submitted to celiac plexus neurolysis who evolved with acute alcohol intoxication diagnosed in the post-anesthetic care unit. CASE REPORT: Female patient, 43 years old, with pancreatic head cancer, submitted to intraoperative celiac plexus neurolysis with 40 mL of 98% alcohol. Patient evolved in the post-anesthetic care unit with hypotension, hypoxemia and mental confusion, which were reverted with intravenous hydration and elevation of lower limbs. CONCLUSION: Celiac plexus alcoholization permanently blocks visceral pain of pancreatic cancer patients, however it is not free of adverse reactions, which may evolve to severe complications if not promptly diagnosed, making mandatory the follow up of patients in the post-anesthetic care unit.